Top

Published in:

Open Access 01-02-2011

HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors

Authors: Robert K. Heaton, Donald R. Franklin, Ronald J. Ellis, J. Allen McCutchan, Scott L. Letendre, Shannon LeBlanc, Stephanie H. Corkran, Nichole A. Duarte, David B. Clifford, Steven P. Woods, Ann C. Collier, Christina M. Marra, Susan Morgello, Monica Rivera Mindt, Michael J. Taylor, Thomas D. Marcotte, J. Hampton Atkinson, Tanya Wolfson, Benjamin B. Gelman, Justin C. McArthur, David M. Simpson, Ian Abramson, Anthony Gamst, Christine Fennema-Notestine, Terry L. Jernigan, Joseph Wong, Igor Grant, for the CHARTER and HNRC Groups

Published in: Journal of NeuroVirology | Issue 1/2011

Abstract

Combination antiretroviral therapy (CART) has greatly reduced medical morbidity and mortality with HIV infection, but high rates of HIV-associated neurocognitive disorders (HAND) continue to be reported. Because large HIV-infected (HIV+) and uninfected (HIV−) groups have not been studied with similar methods in the pre-CART and CART eras, it is unclear whether CART has changed the prevalence, nature, and clinical correlates of HAND. We used comparable methods of subject screening and assessments to classify neurocognitive impairment (NCI) in large groups of HIV + and HIV − participants from the pre-CART era (1988–1995; N = 857) and CART era (2000–2007; N = 937). Impairment rate increased with successive disease stages (CDC stages A, B, and C) in both eras: 25%, 42%, and 52% in pre-CART era and 36%, 40%, and 45% in CART era. In the medically asymptomatic stage (CDC-A), NCI was significantly more common in the CART era. Low nadir CD4 predicted NCI in both eras, whereas degree of current immunosuppression, estimated duration of infection, and viral suppression in CSF (on treatment) were related to impairment only pre-CART. Pattern of NCI also differed: pre-CART had more impairment in motor skills, cognitive speed, and verbal fluency, whereas CART era involved more memory (learning) and executive function impairment. High rates of mild NCI persist at all stages of HIV infection, despite improved viral suppression and immune reconstitution with CART. The consistent association of NCI with nadir CD4 across eras suggests that earlier treatment to prevent severe immunosuppression may also help prevent HAND. Clinical trials targeting HAND prevention should specifically examine timing of ART initiation.

American Academy of Neurology AIDS Task Force (1991) Nomenclature and research case definitions for neurological manifestations of human immunodeficiency virus type-1 (HIV-1) infection. American Academy of Neurology, St. Paul

Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69:1789–1799CrossRefPubMed

Artiola i Fortuny L, Hermosilla Romo D, Heaton RK, Pardee RE III (1999) Manual de normas y procedimientos para la bateiria neuropsicologica en Espanol. m Press, Tucson

Beck AT, Brown GK, Steer RA (1996) Beck depression inventory, 2nd edition manual. The Psychological Corporation, San Antonio

Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561–571PubMed

Brew BJ, Pemberton L, Cunningham P, Law MG (1997) Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis 175:963–966CrossRefPubMed

Centers for Disease Control and Prevention (2008). Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years. Morbidity and Mortality Weekly Reports 57:1–8

Centers for Disease Control and Prevention (1992) HIV surveillance report, 1992. Centers for Disease Control and Prevention, Atlanta, pp 1–23

Centers for Disease Control and Prevention (1994) HIV surveillance report, 2004, vol 6. Centers for Disease Control and Prevention, Atlanta

Centers for Disease Control and Prevention (1996) HIV surveillance report, 1996, vol. 8. Centers for Disease Control and Prevention, Atlanta

Centers for Disease Control and Prevention (2000) HIV surveillance report, 2000, vol 12. Centers for Disease Control and Prevention, Atlanta

Centers for Disease Control and Prevention (2004) HIV surveillance report, 2004, vol 16. Centers for Disease Control and Prevention, Atlanta

Centers for Disease Control and Prevention (2008) HIV surveillance report, 2008. Centers for Disease Control and Prevention, Atlanta

Chelune GJ, Heaton RK, Lehman RA (1986) Neuropsychological and personality correlates of patients complaints of disability. In: Goldstein G, Tarter RE (eds) Advances in clinical neuropsychology, 3rd edn. Plenum, New York, pp 95–126

Childs EA, Lyles RH, Selnes OA, Chen B, Miller EN, Cohen BA, Becker JT, Mellors J, McArthur JC (1999) Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 52:607–613PubMed

Cysique LA, Maruff P, Brew BJ (2004) Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J Neurovirol 10:350–357CrossRefPubMed

Cysique LA, Brew BJ, Halman M, Catalan J, Sacktor N, Price RW, Brown S, Atkinson JH, Clifford DB, Simpson D, Torres G, Hall C, Power C, Marder K, McArthur JC, Symonds W, Romero C (2005) Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patients. J Acquir Immune Defic Syndr 39:426–429CrossRefPubMed

Cysique LA, Vaida F, Letendre S, Gibson S, Cherner M, Woods SP, McCutchan JA, Heaton RK, Ellis RJ (2009) Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 73:342–348CrossRefPubMed

Dore GJ, McDonald A, Li Y, Kaldor JM, Brew BJ (2003) Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 17:1539–1545CrossRefPubMed

Ellis RJ, Deutsch R, Heaton RK, Marcotte TD, McCutchan JA, Nelson JA, Abramson I, Thal LJ, Atkinson JH, Wallace MR, Grant I (1997a) Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego. Arch Neurol 54:416–424PubMed

Ellis RJ, Hsia K, Spector SA, Nelson JA, Heaton RK, Wallace MR, Abramson I, Atkinson JH, Grant I, McCutchan JA (1997b) Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. Ann Neurol 42:679–688CrossRefPubMed

Ferrando S, van Gorp W, McElhiney M, Goggin K, Sewell M, Rabkin J (1998) Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function. AIDS 12:F65–F70CrossRefPubMed

First MB, Spitzer RL, Gibbion M, Williams JBW (1994) Structured clinical interview for axis I DSM-IV disorders, patient edition (SCID-P). Biometrics Research Department, New York State Psychiatric Institute, New York

Grant I, Atkinson JH, Hesselink JR, Kennedy CJ, Richman DD, Spector SA, McCutchan JA (1987) Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections. Studies with neuropsychologic testing and magnetic resonance imaging. Ann Intern Med 107:828–836PubMed

Heaton RK, Grant I, Butters N, White DA, Kirson D, Atkinson JH, McCutchan JA, Taylor MJ, Kelly MD, Ellis RJ et al (1995) The HNRC 500—neuropsychology of HIV infection at different disease stages. J Int Neuropsychol Soc 1:231–251CrossRefPubMed

Heaton RK, Taylor MJ, Manly JJ (2002) Demographic effects and use of demographically corrected norms with the WAIS-III and WMS-III. In: Tulsky D, Saklofske D, Heaton RK, Chelune G, Ivnik R, Bornstein RA, Prifitera A, Ledbetter M (eds) Clinical interpretation of the WAIS-III and WMS-III. Academic, San Diego

Heaton RK, Miller S, Taylor M, Grant I (2004a) Revised comprehensive norms for an expanded Halstead-Reitan Battery: demographically adjusted neuropsychological norms for African American and Caucasian adults scoring program. Psychological Assessment Resources, Lutz

Heaton RK, Marcotte TD, Mindt MR, Sadek J, Moore DJ, Bentley H, McCutchan JA, Reicks C, Grant I (2004b) The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 10:317–331CrossRefPubMed

Heaton RK, Franklin D, Clifford D, Woods SP, Rivera-Mindt M, Vigil O, Taylor MJ, Marcotte T, Atkinson JH, Grant I (2009) HIV-associated neurocognitive impairment (NCI) remains prevalent in the era of combination antiretroviral therapy (CART): the CHARTER Study. In: 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada

Heaton RK, Clifford D, Franklin DR, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil O, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur J, Morgello S, Simpson D, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan T, Wong J, Grant I, for the CHARTER Group (2010). HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75:2087–2096

Hinkin CH, Hardy DJ, Mason KI, Castellon SA, Durvasula RS, Lam MN, Stefaniak M (2004) Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS 18(Suppl 1):S19–S25PubMed

Joska JA, Gouse H, Paul RH, Stein DJ, Flisher AJ (2010) Does highly active antiretroviral therapy improve neurocognitive function? A systematic review. J Neurovirol 16:101–114CrossRefPubMed

Kongs SK, Thompson LL, Iverson GL, Heaton RK (2000) Wisconsin card sorting test-64 card computerized version. Psychological Assessment Resources, Odessa

Letendre SL, McCutchan JA, Childers ME, Woods SP, Lazzaretto D, Heaton RK, Grant I, Ellis RJ (2004) Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol 56:416–423CrossRefPubMed

Marcotte TD, Heaton RK, Wolfson T, Taylor MJ, Alhassoon O, Arfaa K, Ellis RJ, Grant I (1999) The impact of HIV-related neuropsychological dysfunction on driving behavior. J Int Neuropsychol Soc 5:579–592CrossRefPubMed

Marcotte TD, Wolfson T, Rosenthal TJ, Heaton RK, Gonzalez R, Ellis RJ, Grant I (2004) A multimodal assessment of driving performance in HIV infection. Neurology 63:1417–1422PubMed

Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, Ellis RJ, Rodriguez B, Coombs RW, Schifitto G, McArthur JC, Robertson K (2009) Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 23:1359–1366CrossRefPubMed

Mayeux R, Stern Y, Tang MX, Todak G, Marder K, Sano M, Richards M, Stein Z, Ehrhardt AA, Gorman JM (1993) Mortality risks in gay men with human immunodeficiency virus infection and cognitive impairment. Neurology 43:176–182PubMed

McArthur JC, Brew BJ (2010) HIV-associated neurocognitive disorders: is there a hidden epidemic? AIDS 24:1367–1370CrossRefPubMed

McArthur JC, Hoover DR, Bacellar H, Miller EN, Cohen BA, Becker JT, Graham NM, McArthur JH, Selnes OA, Jacobson LP et al (1993) Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology 43:2245–2252PubMed

McArthur JC, McClernon DR, Cronin MF, Nance-Sproson TE, Saah AJ, St Clair M, Lanier ER (1997) Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol 42:689–698CrossRefPubMed

Munoz-Moreno JA, Fumaz CR, Ferrer MJ, Prats A, Negredo E, Garolera M, Perez-Alvarez N, Molto J, Gomez G, Clotet B (2008) Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients. AIDS Res Hum Retroviruses 24:1301–1307CrossRefPubMed

Nath A, Schiess N, Venkatesan A, Rumbaugh J, Sacktor N, McArthur J (2008) Evolution of HIV dementia with HIV infection. Int Rev Psychiatry 20:25–31CrossRefPubMed

Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, McArthur JC, Collier AC, Evans SR, Ellis RJ (2007) The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 21:1915–1921CrossRefPubMed

Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K, De Marcaida JA, Cohen B, Epstein L (2002) HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 8:136–142CrossRefPubMed

Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, Schiffer V, Calmy A, Chave JP, Giacobini E, Hirschel B, Du Pasquier RA (2010) Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 24:1243–1250PubMed

Tozzi V, Balestra P, Serraino D, Bellagamba R, Corpolongo A, Piselli P, Lorenzini P, Visco-Comandini U, Vlassi C, Quartuccio ME, Giulianelli M, Noto P, Galgani S, Ippolito G, Antinori A, Narciso P (2005) Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART. AIDS Res Hum Retroviruses 21:706–713CrossRefPubMed

Tozzi V, Balestra P, Bellagamba R, Corpolongo A, Salvatori MF, Visco-Comandini U, Vlassi C, Giulianelli M, Galgani S, Antinori A, Narciso P (2007) Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr 45:174–182CrossRefPubMed

White DA, Heaton RK, Monsch AU (1995) Neuropsychological studies of asymptomatic human immunodeficiency virus-type-1 infected individuals. J Int Neuropsychol Soc 1:304–315CrossRefPubMed

Woods SP, Rippeth JD, Frol AB, Levy JK, Ryan E, Soukup VM, Hinkin CH, Lazzaretto D, Cherner M, Marcotte TD, Gelman BB, Morgello S, Singer EJ, Grant I, Heaton RK (2004) Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. J Clin Exp Neuropsychol 26:759–778CrossRefPubMed

World Health Organization (1997) Composite international diagnostic interview, version 2.1. WHO, Geneva

Title: HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors
Authors: Robert K. Heaton
Donald R. Franklin
Ronald J. Ellis
J. Allen McCutchan
Scott L. Letendre
Shannon LeBlanc
Stephanie H. Corkran
Nichole A. Duarte
David B. Clifford
Steven P. Woods
Ann C. Collier
Christina M. Marra
Susan Morgello
Monica Rivera Mindt
Michael J. Taylor
Thomas D. Marcotte
J. Hampton Atkinson
Tanya Wolfson
Benjamin B. Gelman
Justin C. McArthur
David M. Simpson
Ian Abramson
Anthony Gamst
Christine Fennema-Notestine
Terry L. Jernigan
Joseph Wong
Igor Grant
for the CHARTER and HNRC Groups
Publication date: 01-02-2011
Publisher: Springer US
Published in: Journal of NeuroVirology / Issue 1/2011
Print ISSN: 1355-0284
Electronic ISSN: 1538-2443
DOI: https://doi.org/10.1007/s13365-010-0006-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

PTEN gene silencing prevents HIV-1 gp120IIIB-induced degeneration of striatal neurons

Human immunodeficiency virus infection in the CNS and decreased dopamine availability: relationship with neuropsychological performance

Genetic and functional heterogeneity of CNS-derived tat alleles from patients with HIV-associated dementia

Chemokines in cerebrospinal fluid correlate with cerebral metabolite patterns in HIV-infected individuals

Successful cognitive aging in persons living with HIV infection

Development of co-selected single nucleotide polymorphisms in the viral promoter precedes the onset of human immunodeficiency virus type 1-associated neurocognitive impairment